Pharmaceutical industry

• Up one level
• How much are we willing to pay for life-saving medications?
  Dave Davies, WHYY Fresh Air, May 14, 2025, 12:47 PM ET. David Armstrong is a senior reporter for ProPublica who focuses on health care. He is also a patient with multiple myeloma, who discovered that a single pill of his prescribed drug Revlimid costs the company about 25 cents to make but is priced at about $1,000. (ProPublica article)
• 'Bottle Of Lies' Exposes The Dark Side Of The Generic-Drug Boom
  Jonathan Lambert, May 12, 2019
  In Bottle of Lies, investigative journalist and author Katherine Eban exposes the dangerous, dark side of some generics. Her propulsive narrative investigation traces the history of the generic-drug boom, revealing how intense demand for cheaper drugs opened a dangerous chasm between what regulations required of drug companies and how some of those companies actually behaved. She also documents how the FDA struggled to address those safety gaps, and the challenges that still remain.
• Drug execs behind female libido pill have run afoul of FDA
  Drug execs behind female libido pill have run afoul of FDA Matthew Perrone, Associated Press, Aug. 14, 2015 Associated Press Writer Mike Householder contributed to this report from Ann Arbor, Michigan. (Archived page courtesy of the Internet Archive's WayBack Machine)
• Greene and Herzberg - HIDDEN in PLAIN SIGHT: Marketing Prescription Drugs to Consumers in the Twentieth Century
  Jeremy A. Greene and David Herzberg. HIDDEN in PLAIN SIGHT: Marketing Prescription Drugs to Consumers in the Twentieth Century . American Journal of Public Health: May 2010, Vol. 100, No. 5, pp. 793-803.
• GSK won't seek patents in low income countries
  GSK won't seek patents in low income countries Alex Dixon, Herald-Sun, Apr 1, 2016
• How Chaos at Chain Pharmacies Is Putting Patients at Risk
  Ellen Gabler, NY Times, Jan 31, 2020.
  Pharmacists across the U.S. warn that the push to do more with less has made medication errors more likely. “I am a danger to the public,” one wrote to a regulator.
• Last Week Tonight with John Oliver: Marketing to Doctors
  Pharmaceutical companies spend billions of dollars marketing drugs to doctors.
• Mylan boosts EpiPen patient programs, doesn't budge on price
  Linda A. Johnson and Tom Murphy, AP Health Writers WRAL, 8/25/2016 Critics stressed that insurers, employers and taxpayers will still foot most of the cost for EpiPens. Over time, that drives up insurance premiums and the country's burgeoning health care tab.
• NY Times - Drug C.E.O. Martin Shkreli Arrested on Fraud Charges
  Drug C.E.O. Martin Shkreli Arrested on Fraud Charges Julie Creswell, Stephanie Clifford, Andrew Pollack, NY Times, Dec 17, 2015
• Orphan drugs
• Robert Whitaker and Lisa Cosgrove - Psychiatry under the influence
  Psychiatry under the influence: institutional corruption, social injury, and prescriptions for reform Robert Whitaker and Lisa Cosgrove Palgrave Macmillan 2015
• Show 997: Big Pharma and Health Care
  Show 997: Big Pharma and Health Care The People's Pharmacy June 18, 2015 What is big pharma's influence on health care in the US and elsewhere? Dr. Peter Gøtzsche worked for the pharmaceutical industry years ago supervising clinical trials and working in regulatory affairs. But this industry insider has become the toughest of critics.